Corbus Pharmaceuticals Holdings (CRBP) Cash & Equivalents (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $27.1 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 123.36% year-over-year to $27.1 million; the TTM figure through Dec 2025 stood at $27.1 million (up 123.36% YoY), while the FY2025 annual figure was $27.1 million, up 123.36% from the prior year.
• Cash & Equivalents was $27.1 million for Q4 2025 at Corbus Pharmaceuticals Holdings, up from $25.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $37.1 million in Q3 2021 to a low of $2.0 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $15.6 million across 5 years, with a median of $15.3 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 83.96% in 2023, then jumped 873.11% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $18.3 million in 2021, then plunged by 79.16% to $3.8 million in 2022, then jumped by 154.79% to $9.7 million in 2023, then climbed by 25.33% to $12.2 million in 2024, then soared by 123.36% to $27.1 million in 2025.
• The last three Cash & Equivalents figures came in at $27.1 million (Q4 2025), $25.5 million (Q3 2025), and $17.8 million (Q2 2025), per Business Quant data.